Is Topical Bicalutamide a Safer Alternative to Finasteride?

Finasteride has long been one of the most commonly used treatments for androgenetic alopecia in men, also known as male pattern baldness. Concerns about its side effects, particularly in the oral form, have driven interest in other options — including applying to the scalp drugs that were previously only taken systemically. Topical bicalutamide is one of those. This article sets out what the published record actually contains on that question. The short version: topical bicalutamide has no published human trial in androgenetic alopecia, so it cannot be described as safer, or as effective, on evidence.

What is Finasteride Used For and How Is It Consumed?

Finasteride is an FDA-approved medication for treating androgenetic alopecia in men and is also used for benign prostatic hyperplasia (enlarged prostate). Its mechanism of action involves inhibiting 5-alpha reductase type II, the enzyme that converts testosterone into dihydrotestosterone (DHT). DHT is the hormone primarily responsible for the miniaturization of hair follicles in male pattern baldness. The label doses are 1 mg per day for hair loss and 5 mg per day for prostate indications. In recent years it has also been formulated topically in an effort to limit systemic exposure. Studied and marketed topical strengths are around 0.25%, which is approximately 2.5 mg per ml of solution, depending on the manufacturer and the vehicle used.

Even in its topical form, finasteride is absorbed into the bloodstream to some degree, and side effects are therefore possible.

What is Bicalutamide and How Does It Work on Hair?

Bicalutamide is a non-steroidal antiandrogen developed and approved for the treatment of prostate cancer. It blocks androgen receptors, preventing hormones such as testosterone or DHT from binding to cells and triggering their downstream effects. Unlike finasteride, which reduces DHT production, bicalutamide competes with DHT at the receptor. That mechanism is why it has been discussed in hair dermatology, since androgenetic alopecia is driven by DHT acting on the follicle. Orally, the usual prostate-cancer dose is 50 mg per day; that use is not approved for hair loss, and neither is any other.

Topical bicalutamide is not a marketed product anywhere. There is no licensed topical bicalutamide, so any topical version is either compounded to a prescriber's order by a pharmacy or mixed by the user from bulk powder. Concentrations quoted in community discussion are typically 0.5% to 1%, but those figures come from that discussion rather than from a published trial, and a home-mixed antiandrogen has no assurance of purity, dose accuracy, stability or scalp penetration. This article does not describe how to make one.

Is Topical Bicalutamide Safer Than Oral Finasteride?

This is the question most people arrive with, and the honest answer is that the evidence to answer it does not exist. A search of PubMed for published human studies of topical bicalutamide in androgenetic alopecia returns none: no randomized trial, no controlled study, and no clinical case series of the topical route in this indication. What exists is laboratory work on delivery — for example, formulation studies of bicalutamide in lipid vesicles, niosomes and microarray patches, which measure how the drug crosses skin in the lab and say nothing about hair outcomes or safety in people.

An earlier version of this article described two studies in support of topical bicalutamide: a 2021 pilot in Skin Appendage Disorders in 16 men on 0.5% solution, and a 2022 observational study in the International Journal of Trichology in 30 patients on 1% gel, both reporting improvement with no systemic effects. Neither study could be found in PubMed or at the publisher, and the DOI given for the first resolves to nothing. Both descriptions, and both references, have been removed. They should not be repeated elsewhere.

Oral finasteride, in contrast, has been studied at scale. A double-blind clinical trial published in 1998 in the Journal of the American Academy of Dermatology followed 1,553 men for two years. It reported that 83% of men taking 1 mg of oral finasteride daily had no further hair loss, with regrowth in a proportion of them. Drug-related sexual adverse events were reported by a small percentage of men, modestly above placebo — the trial recorded these as reversible on discontinuation. Some men report that symptoms persisted after they stopped the drug; this is discussed as "post-finasteride syndrome", a description that remains contested and is not an established diagnosis with an agreed definition or mechanism. It is a real reported experience and an open question, not a settled entity.

What About Topical Finasteride?

Topical finasteride, unlike topical bicalutamide, has been through a controlled trial. A phase III randomized, controlled trial published in 2022 in the Journal of the European Academy of Dermatology and Venereology tested a topical finasteride spray solution in men with androgenetic alopecia. It reported improvement in target-area hair count against vehicle, with substantially lower plasma DHT suppression than oral finasteride produces.

Absorption is reduced, not eliminated. Measurable finasteride reaches the blood from topical use, so systemic effects remain possible, and the trial durations so far are short relative to how long people take these drugs. Topical finasteride is therefore a lower-exposure option with real trial data behind it — not a risk-free one.

User Experiences: Is Topical Bicalutamide a Safer Alternative to Finasteride?

In the Tressless community, a recurring discussion is whether topical bicalutamide is a safer or more targeted option than oral finasteride. The reasoning users give is that finasteride works systemically by inhibiting 5-alpha-reductase and lowering serum DHT, whereas bicalutamide blocks the androgen receptor, which they hope means fewer systemic hormonal effects when applied to the scalp. That is a hypothesis about a compound with no human topical data, not a finding.

In discussions such as this post, one female user described considering bicalutamide as part of a broader antiandrogen protocol including estrogen and spironolactone. Community users report that topical bicalutamide is explored mainly by women and by trans people, particularly where systemic DHT suppression from finasteride is unsuitable or has caused unwanted effects. Others describe combining it with topical estrogens or tretinoin, with the stated aim of local antiandrogenic activity without changing testosterone levels. These are stated intentions, not measured outcomes; nobody in these threads has plasma levels or a control group.

Among male users, enthusiasm is more tempered. Several raise systemic absorption, and point out that bicalutamide is not approved for hair loss and that its long-term safety as a topical is unstudied. Bicalutamide taken orally carries a hepatotoxicity warning and requires liver-function monitoring, which is the specific reason absorption from a scalp product matters rather than a theoretical worry. A few anecdotal posts report perceived maintenance or regrowth without finasteride-type side effects. An older and still frequently cited post compares bicalutamide with RU58841 and flutamide. RU58841 is an unapproved research chemical that has never completed human trials and is not available as a medicine; flutamide is a prescription antiandrogen carrying a boxed warning for severe liver injury. Clascoterone is the one topical antiandrogen in this group with regulatory approval, and that approval is for acne, not for hair loss.

Talk to a doctor or pharmacist before starting, stopping or combining finasteride, bicalutamide or any antiandrogen — including any compounded topical version. Bicalutamide is contraindicated in pregnancy and can harm a developing fetus, so anyone who is or may become pregnant should not use or handle it.

Conclusion: Is Topical Bicalutamide Safer Than Finasteride?

The comparison cannot be made from evidence. Topical bicalutamide has no published human trial in androgenetic alopecia, no marketed product, and no established dose, so nothing is known about how well it works or how much of it reaches the bloodstream from the scalp. "No reported side effects" in that situation means nobody has looked, not that there are none. Oral finasteride has decades of trial and post-marketing data behind it, including a documented side-effect profile that some men find unacceptable — but that documentation is itself the difference between the two options.

Topical finasteride sits in between: a lower-exposure formulation with a phase III trial behind it, still absorbed to a measurable degree, and still a prescription decision. Anyone weighing these options should make that decision with a doctor who knows their history, rather than from forum consensus about a compound that has not been tested in people.

References

• Kaufman, K. D., Olsen, E. A., Whiting, D., Savin, R., DeVillez, R., Bergfeld, W., et al., & Finasteride Male Pattern Hair Loss Study Group. (1998). Finasteride in the treatment of men with androgenetic alopecia. Journal of the American Academy of Dermatology, 39(4), 578–589. PMID 9777765. https://doi.org/10.1016/S0190-9622(98)70007-6

• Piraccini, B. M., Blume-Peytavi, U., Scarci, F., et al. (2022). Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. Journal of the European Academy of Dermatology and Venereology, 36(2), 286–294. PMID 34634163. https://doi.org/10.1111/jdv.17738

• Carvalho, R. M., Santos, L. D. N., Ramos, P. M., Machado, C. J., Acioly, P., Frattini, S. C., Barcaui, C. B., Donda, A. L. V., & Melo, D. F. (2022). Bicalutamide and the new perspectives for female pattern hair loss treatment: What dermatologists should know. Journal of Cosmetic Dermatology, 21(10), 4171–4175. PMID 35032336. https://doi.org/10.1111/jocd.14773

• FDA. (2024). Drug label for finasteride. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/020788s041lbl.pdf